{"nctId":"NCT00667602","briefTitle":"Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers","startDateStruct":{"date":"2008-03"},"conditions":["Meningococcal Meningitis"],"count":662,"armGroups":[{"label":"MenACWY-CRM197 (2 doses) + Concomitant Vaccines","type":"EXPERIMENTAL","interventionNames":["Biological: MenACWY-CRM197 (two doses)","Biological: PCV7","Biological: DTPa-IPV-HepB-Hib"]},{"label":"MenACWY-CRM197 (1 dose) + Concomitant Vaccines","type":"EXPERIMENTAL","interventionNames":["Biological: PCV7","Biological: DTPa-IPV-HepB-Hib","Biological: MenACWY-CRM197 (one dose)"]},{"label":"MenC (1 dose) + Concomitant Vaccines","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: MenC","Biological: PCV7","Biological: DTPa-IPV-HepB-Hib"]}],"interventions":[{"name":"MenACWY-CRM197 (two doses)","otherNames":[]},{"name":"MenC","otherNames":[]},{"name":"PCV7","otherNames":[]},{"name":"DTPa-IPV-HepB-Hib","otherNames":[]},{"name":"MenACWY-CRM197 (one dose)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* infants 6 to 8 months old inclusive, who were born after full term pregnancy and previously received three doses of both Prevenar and Infanrix-hexa vaccines at least 30 days before study entry\n\nExclusion Criteria:\n\n* who previously received any meningococcal vaccine;\n* who have had a previous confirmed or suspected disease caused by N. meningitidis, C. diphtheriae, C. tetani, Poliovirus, Hepatitis B, Hib, Pneumococcus or B. pertussis;\n* who have had household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis (serogroups A, C, W135, or Y), B. pertussis, Hib, C. diphtheriae, Polio, or pneumococcal infection at any time since birth;\n* Subjects with any serious, acute or chronic progressive disease","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"8 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentages of Subjects With Serum Bactericidal Titer ≥ 1:8 Against N.Meningitidis Serogroup C","description":"Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was measured using serum bactericidal assay with human complement (hSBA) titer ≥ 1:8 against N.meningitidis serogroup C.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"92","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:4 Against N.Meningitidis Serogroup C","description":"Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentage of subjects with serum bactericidal activity using human complement (hSBA) titers ≥ 1:4 against N. meningitidis serogroup C.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, C, W, Y","description":"1. Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month postvaccination was assessed and compared as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8, ≥ 1:4 against N.meningitidis Serogroup C.\n2. Immunogenicity of two doses of MenACWY-CRM197 vaccine one month postvaccination was assessed as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8, ≥ 1:4 against N.meningitidis Serogroup A, W, Y.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, W, Y","description":"Immunogenicity for one dose of MenACWY was assessed as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8 and titer ≥ 1:4 by serogroups A, W, Y.\n\nSerogroup C is not shown here as it is shown in other outcome measures.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Human Serum Bactericidal Activity Geometric Mean Titers After One Dose of MenACWY-CRM197 and MenC Against N.Meningitidis Serogroup C","description":"Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed with geometric mean titer (GMT) of serum bactericidal assay with human complement (hSBA) against N. meningitidis serogroup C.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":null},{"groupId":"OG001","value":"2.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, W, Y","description":"Immunogenicity of one dose of MenACWY-CRM197 one month postvaccination was assessed with GMT of serum bactericidal assay with hSBA against Serogroups A, W, Y.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, C, W, Y","description":"1. The immunogenicity of two doses of MenACWY-CRM197, to a single dose of MenC was assessed and compared as measured by human Serum Bactericidal Activity Geometric Mean Titers directed against N. meningitidis serogroup C.\n2. The immunogenicity of two doses of MenACWY-CRM197, to a single dose of MenC was assessed as measured by human Serum Bactericidal Activity Geometric Mean Titers directed against N. meningitidis serogroups A, W, Y.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"2.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"2.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"249","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"1.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"1.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"1.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Seroresponse Rates After One Dose of DTPa-IPV-HepB-Hib (Concomitant Vaccine)","description":"The immunogenicity of one dose of MenC to one dose of DTPa-IPV-HepB-Hib concomitant vacccine was assessed.\n\nFor Pertussis antigens, Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN), the seroresponse in initially seronegative subjects (pre-vaccination antibody concentration \\< LLQ) is defined as post-vaccination antibody concentration \\>= LLQ; in initially seropositive subjects (pre-vaccination antibody concentration \\>=LLQ) seroresponse is defined as at least two fold increase of the pre-vaccination antibody concentration.\n\nDiptheria and Tetanus: primary endpoint ELISA (Enzyme-linked immunosorbent assay) \\>=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA\\>=1.0 IU/mL.\n\nPolio type 1, 2 and 3: bNT (neutralization test) with \\>=1:8.\n\nHepB (HBV): primary endpoint ELISA \\>=10mU/mL.\n\nPRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Seroresponse Rates After One Dose of PCV7 (Concomitant Vaccine)","description":"To compare the immunogenicity of PCV7 (Pneumococcal 7-valent Conjugate)Vaccine when given concomitantly with one dose or two doses of MenACWY-CRM197 or with MenC to infants at 12 months of age.\n\nSeroresponse for PCV7 (PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F, PnC 23F) is defined as: a subject with primary endpoint ELISA ≥ 0.35 mcg/mL and secondary endpoint ELISA ≥ 1.0 mcg/mL.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Persistence of Immune Response Measured as Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroup C","description":"Persistence of immune response to either one or two doses of MenACWY-CRM197 or one dose of MenC as measured by serum bactericidal assay with human complement (hSBA) titers ≥ 1:8, and titers ≥ 1:4 directed against N.meningitidis serogroup C (only for subjects enrolled in Australia).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"77","spread":null}]}]}]},{"type":"SECONDARY","title":"Persistence of Immune Response Measured as Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 ,and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, W, Y","description":"Persistence of immune response to either one or two doses of MenACWY-CRM197 or one dose of MenC as measured by serum bactericidal assay with human complement (hSBA) titer ≥ 1:8 and titer ≥ 1:4 directed against N. meningitidis serogroups A, W and Y (only for subjects enrolled in Australia).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Persistence of Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup C","description":"Persistence of immunogenicity of either one or two doses of MenACWY or one dose of MenC as measured by human serum bactericidal activity geometric mean titers directed against N.meningitidis serogroup C (only for subjects enrolled in Australia).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"241","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"8.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Persistence of Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, W, Y","description":"Immunogenicity of two doses of MenACWY to one dose of MenACWY as measured by hSBA GMTs directed against N.meningitidis serogroups A, W, Y (only for subjects enrolled in Australia).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"6.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.41","spread":null},{"groupId":"OG001","value":"2.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"180","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"5.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Rabbit Serum Bactericidal ≥ 1:8, ≥ 1:128 and Four Fold Rise Against N.Meningitidis Serogroup C","description":"1. Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup C.\n2. Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup C.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"92","spread":null},{"groupId":"OG002","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"91","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With Rabbit Serum Bactericidal ≥ 1:8, ≥ 1:128, and Four Fold Rise Against N.Meningitidis Serogroup A, W, Y","description":"1. Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup A, W, Y.\n2. Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup A, W, Y.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]}]},{"type":"SECONDARY","title":"Rabbit Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup C","description":"1. Immunogenicity of one dose of MenACWY-CRM197 to one dose of MenC vaccine at 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup C.\n2. Immunogenicity of two doses of MenACWY-CRM197 to one dose of MenC vaccine at 6 to 8 and 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup C.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"2.22","spread":null},{"groupId":"OG002","value":"2.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"353","spread":null},{"groupId":"OG001","value":"131","spread":null},{"groupId":"OG002","value":"266","spread":null}]}]}]},{"type":"SECONDARY","title":"Rabbit Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup A, W, Y","description":"1. Immunogenicity of one dose of MenACWY-CRM197 to one dose of MenC vaccine at 12 months of age was assessed with GMT of SBA with rabbit complement (rSBA) against Serogroup A, W, Y.\n2. Immunogenicity of two doses of MenACWY-CRM197 to one dose of MenC vaccine at 6 to 8 and 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup A, W, Y.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"281","spread":null},{"groupId":"OG001","value":"6.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3136","spread":null},{"groupId":"OG001","value":"3258","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"2.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"708","spread":null},{"groupId":"OG001","value":"1306","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"574","spread":null},{"groupId":"OG001","value":"598","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Reported Solicited Local and Systemic Reactions (Day 1 to Day 7 Postvaccination), After Any Vaccination","description":"Safety was assessed as the number of subjects who reported solicited local reactions from day 1 to day 7 postvaccination for all the three vaccination groups.\n\nsafety was assessed as the number of subjects who reported solicited systemic reactions from day 1 to day 7 Following the Month 12 vaccination in all three vaccination groups","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"131","spread":null},{"groupId":"OG002","value":"135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"149","spread":null},{"groupId":"OG002","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":195},"commonTop":["Pyrexia","Injection site erythema","Somnolence","Injection site induration","Injection site pain"]}}}